ALHC insider files to sell 24,800 shares valued $391,840
Rhea-AI Filing Summary
Alignment Healthcare insider sale notice: The filing reports that 24,800 shares of Alignment Healthcare common stock are proposed for sale via Morgan Stanley Smith Barney, with an aggregate market value of $391,840, and an approximate sale date of 08/22/2025 on NASDAQ. The shares were acquired 03/06/2021 as pre-IPO shares issued in exchange for partnership units. The filer reports two prior 10b5-1 sales by Hyong J Kim on 08/11/2025 and 08/13/2025, each showing 18,600 shares sold generating gross proceeds of $270,425.40 and $279,608.22 respectively. The filing includes the standard representation that the seller is not aware of undisclosed material adverse information.
Positive
- Detailed disclosure of planned sale amount (24,800 shares), broker (Morgan Stanley Smith Barney), and aggregate value ($391,840)
- Source of shares disclosed: acquired 03/06/2021 as pre-IPO issuance in exchange for partnership units
- Prior 10b5-1 sales disclosed (08/11/2025 and 08/13/2025), indicating use of a documented trading plan
Negative
- Insider selling activity: multiple recent sales (two prior 18,600-share transactions plus the proposed 24,800-share sale) reduce insider ownership
- Limited financial context: filing contains no explanation of purpose for sale or impact on insider ownership percentage
Insights
TL;DR: Insider plans to sell a modest parcel of shares; prior 10b5-1 transactions occurred in August 2025.
The notice documents a proposed sale of 24,800 common shares valued at $391,840, sourced from pre-IPO partnership-unit issuance on 03/06/2021. Sales will be executed through Morgan Stanley Smith Barney and are scheduled for 08/22/2025. The filing also discloses two recent 10b5-1 sales by Hyong J Kim on 08/11/2025 and 08/13/2025 of 18,600 shares each. For investors, this is a routine insider liquidity event; the amounts are small relative to the issuer's reported outstanding shares of 198,031,417, so market impact is likely limited.
TL;DR: Filing shows compliance with Rule 144 and disclosure of 10b5-1 sales, indicating adherence to trading-plan transparency.
The document specifies that the securities were acquired pre-IPO and that the seller affirms no undisclosed material adverse information. The inclusion of 10b5-1 sale details and broker information suggests adherence to established insider-trading protocols. From a governance perspective, the filing provides required transparency about the timing, source, and mechanism of insider sales but does not contain additional governance changes or material corporate events.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When is the proposed sale scheduled for ALHC?
How and when were the securities being sold originally acquired?
Who is the broker handling the proposed ALHC sale?
AI-generated analysis. How Rhea-AI works. Not financial advice.